Palatin Technologies, Inc. Reports Third Quarter Fiscal Year 2011 Results
CRANBURY, N.J., May 16, 2011 /PRNewswire/ — Palatin Technologies, Inc. (NYSE Amex: PTN), a biopharmaceutical company developing bremelanotide for sexual dysfunction indications and PL-3994 for acute asthma and other indications, today announced results for its third quarter ended March 31, 2011. Recent Highlights Following a meeting with the U.S. Food and Drug Administration (FDA), Palatin …
Palatin Technologies, Inc. Reports Third Quarter Fiscal Year 2011 Results Read More »